A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD
- Atopic Dermatitis
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Bambusa Therapeutics
- Enrolment target
- 237
- Started
- 27 February 2025
- Main results due
- 28 February 2027
- Study sites
- 14
- Registry updated
- 29 September 2026
Can you take part?
- Ages 18 years to 72 years.
- Open to any sex.
- Healthy volunteers can take part.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Key Inclusion Criteria 1. Negative pregnancy tests for women of childbearing potential. 2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit. 3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers. 4. Adequate contraception use (for men and women of childbearing potential). Key Inclusion Criteria (Parts A, B, and D) 1. Age of 18-65 years. 2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg. 3. No clinically significant abnormalities or history of relevant diseases. Key Inclusion Criteria (Parts C and E only) 1. Age of 18-72 years. 2. Body mass index ≥16 kg/m², weight capped at 125 kg. 3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable. 4. Moderate to severe atopic dermatitis 5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3 6. Atopic lesions cover ≥10% of body surface area (BSA) 7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization. Key Exclusion Criteria 1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections. 2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders. 3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function. 4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1. 5. Abnormal Electrocardiogram (ECG) findings 6. History of drug/alcohol abuse in the past 2 years. 7. Donated \>500mL blood within 2 months of screening. 8. History of severe allergic reactions or hypersensitivity. Key Exclusion Criteria (Parts A, B, and D only) 1\. History of atopic dermatitis Key Exclusion Criteria (Parts C and E only) 1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring. 2. Receipt of immunoglobulin or blood products within 30 days. 3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use. 4. Chronic pruritus from conditions other than atopic dermatitis. 5. Acute/treated infections or chronic skin infections. 6. Current use of sedating antihistamines or corticosteroids.
What this study is about
In the sponsor’s own words, from the registry.
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Study sites(14)
First OC Dermatology
Irvine, California, United States
Recruiting
OptiSkin Medical
New York, New York, United States
Recruiting
Equity Medical, LLC
The Bronx, New York, United States
Recruiting
Fremantle Dermatology
Fremantle, Western Australia, Australia
Recruiting
Linear Clinical Research
Perth, Western Australia, Australia
Completed
Optimal Clinical Trials Central Auckland
Grafton, Auckland, New Zealand
Recruiting
Aotearoa Clinical Trials
Otahuhu, Auckland, New Zealand
Withdrawn
Pacific Clinical Research Network (PCRN) - Auckland
Takapuna, Auckland, New Zealand
Recruiting
Optimal Clinical Trials Ltd - Christchurch
Christchurch, New Zealand
Recruiting
Pacific Clinical Research Network (PCRN) Wellington
Upper Hutt, New Zealand
Recruiting
Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
Lodz, Poland
Recruiting
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
Rzeszów, Poland
Recruiting
Państwowy Instytut Medyczny MSWiA
Warsaw, Poland
Recruiting
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
Wroclaw, Poland
Recruiting
Showing 14 of 14 sites. 12 of the 14 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06808477. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me